FDA conditionally approves Liavium-CA1 for canine CM/SM pain

The FDA has conditionally approved Liavium-CA1, a pregabalin chewable tablet from Ireland-based TriviumVet, for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. Announced May 12, 2026, the decision gives veterinarians the first FDA-cleared product specifically labeled for this indication in the U.S. Liavium-CA1 is a prescription-only, twice-daily oral therapy given with food, and FDA says it may be used alongside an NSAID. The agency noted the drug was eligible for expanded conditional approval because CM/SM is a serious condition, there is no approved U.S. animal drug currently marketed for this use, and proving effectiveness requires advanced imaging and difficult study design. (fda.gov)

Why it matters: For veterinary professionals, this formalizes a treatment pathway for a painful neurologic syndrome that has long been managed with off-label options, especially in toy and small breeds such as Cavalier King Charles Spaniels. FDA’s FOI summary shows the approval relied on published clinical studies supporting pregabalin at 5 to 10 mg/kg twice daily, with evidence of reduced pain and scratching-related clinical signs; reported adverse effects included sedation, ataxia, somnolence, increased appetite, and increased water intake at higher doses. Dogs under 3 kg can’t be accurately dosed with the product, and because pregabalin is a Schedule V controlled substance, handling, prescribing, and client counseling will matter in everyday practice. (animaldrugsatfda.fda.gov)

What to watch: TriviumVet now has up to five years to generate the additional effectiveness data needed for full approval, so watch for label uptake, post-market experience, and future FDA renewal filings. (fda.gov)